Details of the Drug

General Information of Drug (ID: DMRKTCP)

Drug Name
Retifanlimab
Synonyms MGA012; INCMGA0012
Indication
Disease Entry ICD 11 Status REF
Neuroendocrine cancer 2B72.1 Approved [1]
Non-small-cell lung cancer 2C25.Y Phase 3 [2]
Merkel cell carcinoma 2C34 Phase 2 [3]
Metastatic colorectal cancer 2B91 Phase 2 [4]
Penile squamous cancer 2C81 Phase 1 [5]
Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
⏷ Show the Full List of Indication(s)
Affected Organisms
Humans and other mammals
ATC Code
L01FF10: Retifanlimab
L01FF: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Antibody
Cross-matching ID
UNII
2Y3T5IF01Z
DrugBank ID
DB15766
TTD ID
D0PG5O
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Inhibitor [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Neuroendocrine cancer
ICD Disease Classification 2B72.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761334.
2 ClinicalTrials.gov (NCT04203511) INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT03599713) A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201). U.S. National Institutes of Health.
4 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
5 ClinicalTrials.gov (NCT04231981) Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS) (ORPHEUS). U.S. National Institutes of Health.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)